InsuletPODD
About: Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
Employees: 3,900
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
150% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 5 (+3) [Q4]
135% more first-time investments, than exits
New positions opened: 122 | Existing positions closed: 52
13% more capital invested
Capital invested by funds: $16.2B [Q3] → $18.4B (+$2.19B) [Q4]
10% more repeat investments, than reductions
Existing positions increased: 244 | Existing positions reduced: 221
10% more funds holding
Funds holding: 610 [Q3] → 668 (+58) [Q4]
1.04% more ownership
Funds ownership: 99.36% [Q3] → 100.41% (+1.04%) [Q4]
31% less call options, than puts
Call options by funds: $123M | Put options by funds: $177M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
RBC Capital Shagun Singh 38% 1-year accuracy 25 / 66 met price target | 39%upside $340 | Outperform Initiated | 6 Mar 2025 |
Citigroup Joanne Wuensch 39% 1-year accuracy 16 / 41 met price target | 45%upside $355 | Buy Maintained | 21 Feb 2025 |
Raymond James Jayson Bedford 43% 1-year accuracy 12 / 28 met price target | 34%upside $328 | Outperform Reiterated | 21 Feb 2025 |
Stifel Mathew Blackman 24% 1-year accuracy 4 / 17 met price target | 20%upside $293 | Hold Maintained | 21 Feb 2025 |
Piper Sandler Matt O'Brien 32% 1-year accuracy 16 / 50 met price target | 27%upside $310 | Overweight Maintained | 21 Feb 2025 |
Financial journalist opinion
Based on 7 articles about PODD published over the past 30 days
